Coeptis Therapeutics Holdings, Inc.
NASDAQ Global MarketTotal Valuation
Coeptis Therapeutics Holdings, Inc. carries a market capitalization of 64,721.00, placing it among publicly traded companies globally. Its enterprise value stands at -5.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 64,721.00 |
| Enterprise Value | -5.58M |
Share Statistics
Coeptis Therapeutics Holdings, Inc. currently has 5.75M shares outstanding.
| Shares Outstanding | 5.75M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Coeptis Therapeutics Holdings, Inc. maintains a current ratio of 4.16, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.91, indicating elevated leverage, while an interest coverage ratio of -18.40 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.16 |
| Quick Ratio | 3.60 |
| Debt / Equity | 1.91 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -18.40 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -87.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Coeptis Therapeutics Holdings, Inc.'s stock has declined approximately -56.66667% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -56.66667% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.82M, while operating income came in at -13.04M.
| Revenue | 1.36M |
| Gross Profit | 1.18M |
| Operating Income | -13.04M |
| Pretax Income | -12.28M |
| Net Income | -10.91M |
| EBITDA | -11.82M |
| EBIT | -13.04M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Coeptis Therapeutics Holdings, Inc. holds 6.35M in cash and equivalents against 268,875.00 in total debt, resulting in a net debt position of -5.42M. Total book value stands at -109.95M, with working capital of 5.58M providing operational flexibility.
| Cash & Cash Equivalents | 6.35M |
| Total Debt | 268,875.00 |
| Net Debt | -5.42M |
| Equity (Book Value) | -109.95M |
| Book Value Per Share | N/A |
| Working Capital | 5.58M |
Cash Flow
Coeptis Therapeutics Holdings, Inc. produced -8.60M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.60M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.60M |
| FCF Per Share | N/A |
Margins
Coeptis Therapeutics Holdings, Inc. operates with a gross margin of 86.75, reflecting its pricing power and cost economics. The operating margin of -956.94 and net profit margin of -800.38 provide insight into operational efficiency.
| Gross Margin | 86.75 |
| Operating Margin | -956.94 |
| Pretax Margin | -900.72 |
| Profit Margin | -800.38 |
| EBITDA Margin | -867.24 |
Scores
Coeptis Therapeutics Holdings, Inc. posts an Altman Z-Score of -12.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.40 |